165 related articles for article (PubMed ID: 15670914)
1. Understanding topoisomerase I and II in terms of QSAR.
Verma RP
Bioorg Med Chem; 2005 Feb; 13(4):1059-67. PubMed ID: 15670914
[TBL] [Abstract][Full Text] [Related]
2. 20-(S)-camptothecin analogues as DNA topoisomerase I inhibitors: a QSAR study.
Hansch C; Verma RP
ChemMedChem; 2007 Dec; 2(12):1807-13. PubMed ID: 17886246
[TBL] [Abstract][Full Text] [Related]
3. [Inhibitors of DNA topoisomerases].
Andoh T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory activities against topoisomerase I and II by polyhydroxybenzoyl amide derivatives and their structure-activity relationship.
Abdel-Aziz M; Matsuda K; Otsuka M; Uyeda M; Okawara T; Suzuki K
Bioorg Med Chem Lett; 2004 Apr; 14(7):1669-72. PubMed ID: 15026047
[TBL] [Abstract][Full Text] [Related]
5. Cationic porphyrins and analogues as new DNA topoisomerase I and II inhibitors.
Shuai L; Wang S; Zhang L; Fu B; Zhou X
Chem Biodivers; 2009 Jun; 6(6):827-37. PubMed ID: 19551725
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory activities against topoisomerase I and II by isoaurostatin derivatives and their structure-activity relationships.
Suzuki K; Okawara T; Higashijima T; Yokomizo K; Mizushima T; Otsuka M
Bioorg Med Chem Lett; 2005 Apr; 15(8):2065-8. PubMed ID: 15808469
[TBL] [Abstract][Full Text] [Related]
7. QSAR studies about cytotoxicity of benzophenazines with dual inhibition toward both topoisomerases I and II: 3D-MoRSE descriptors and statistical considerations about variable selection.
Saíz-Urra L; González MP; Teijeira M
Bioorg Med Chem; 2006 Nov; 14(21):7347-58. PubMed ID: 16962784
[TBL] [Abstract][Full Text] [Related]
8. On the physical interpretation of QSAR models.
Stanton DT
J Chem Inf Comput Sci; 2003; 43(5):1423-33. PubMed ID: 14502475
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of DNA topoisomerase I and II isolated from the Coptis rhizomes.
Kobayashi Y; Yamashita Y; Fujii N; Takaboshi K; Kawakami T; Kawamura M; Mizukami T; Nakano H
Planta Med; 1995 Oct; 61(5):414-8. PubMed ID: 7480201
[TBL] [Abstract][Full Text] [Related]
10. Relationships between topoisomerase II inhibition, sequence-specificity and DNA binding mode of dicationic diphenylfuran derivatives.
Bailly C; Dassonneville L; Carrasco C; Lucas D; Kumar A; Boykin DW; Wilson WD
Anticancer Drug Des; 1999 Feb; 14(1):47-60. PubMed ID: 10363027
[TBL] [Abstract][Full Text] [Related]
11. Chromophore-modified bisnaphthalimides: DNA recognition, topoisomerase inhibition, and cytotoxic properties of two mono- and bisfuronaphthalimides.
Bailly C; Carrasco C; Joubert A; Bal C; Wattez N; Hildebrand MP; Lansiaux A; Colson P; Houssier C; Cacho M; Ramos A; Braña MF
Biochemistry; 2003 Apr; 42(14):4136-50. PubMed ID: 12680768
[TBL] [Abstract][Full Text] [Related]
12. Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors.
Pinar A; Yurdakul P; Yildiz I; Temiz-Arpaci O; Acan NL; Aki-Sener E; Yalcin I
Biochem Biophys Res Commun; 2004 Apr; 317(2):670-4. PubMed ID: 15063810
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, cytotoxic activity, DNA topoisomerase-II inhibition, molecular modeling and structure-activity relationship of 9-anilinothiazolo[5,4-b]quinoline derivatives.
Loza-Mejía MA; Olvera-Vázquez S; Maldonado-Hernández K; Guadarrama-Salgado T; González-Sánchez I; Rodríguez-Hernández F; Solano JD; Rodríguez-Sotres R; Lira-Rocha A
Bioorg Med Chem; 2009 May; 17(9):3266-77. PubMed ID: 19364657
[TBL] [Abstract][Full Text] [Related]
14. Anthocyanidins modulate the activity of human DNA topoisomerases I and II and affect cellular DNA integrity.
Habermeyer M; Fritz J; Barthelmes HU; Christensen MO; Larsen MK; Boege F; Marko D
Chem Res Toxicol; 2005 Sep; 18(9):1395-404. PubMed ID: 16167831
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerases of kinetoplastid parasites: why so fascinating?
Das BB; Sengupta T; Ganguly A; Majumder HK
Mol Microbiol; 2006 Nov; 62(4):917-27. PubMed ID: 17042788
[TBL] [Abstract][Full Text] [Related]
16. Benzothiopyranoindole-based antiproliferative agents: synthesis, cytotoxicity, nucleic acids interaction, and topoisomerases inhibition properties.
Dalla Via L; Magno SM; Gia O; Marini AM; Da Settimo F; Salerno S; La Motta C; Simorini F; Taliani S; Lavecchia A; Di Giovanni C; Brancato G; Barone V; Novellino E
J Med Chem; 2009 Sep; 52(17):5429-41. PubMed ID: 19725581
[TBL] [Abstract][Full Text] [Related]
17. Cellular, pharmacokinetic, and pharmacodynamic aspects of response to camptothecins: can we improve it?
Jung LL; Zamboni WC
Drug Resist Updat; 2001 Aug; 4(4):273-88. PubMed ID: 11998845
[TBL] [Abstract][Full Text] [Related]
18. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II.
Stuchlík S; Turna J; Miko M
J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355
[TBL] [Abstract][Full Text] [Related]
19. 2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Basnet A; Thapa P; Karki R; Na Y; Jahng Y; Jeong BS; Jeong TC; Lee CS; Lee ES
Bioorg Med Chem; 2007 Jul; 15(13):4351-9. PubMed ID: 17493824
[TBL] [Abstract][Full Text] [Related]
20. 3D-QSAR study on heterocyclic topoisomerase II inhibitors using CoMSIA.
Tekiner-Gulbas B; Temiz-Arpaci O; Yildiz I; Aki-Sener E; Yalcin I
SAR QSAR Environ Res; 2006 Apr; 17(2):121-32. PubMed ID: 16644553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
